A lady at the grocery store shows that every single thing she picks up now says “Contains bioengineered ingredients”
“I'm here at Aldi, and almost everything they have contains bioengineered food ingredients.” This is all fake food."
@ElephantSignal Good luck getting any providers to prescribe this. We live in Missouri and have been trying to get a prescription for our son ever since we heard about it.
A Cancer Breakthrough That Changes Everything
In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed.
This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system.
Here’s the revolutionary breakdown:
1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells.
2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer.
The Proven Results:
- Metastatic Pancreatic Cancer: Patients alive 6 years later.
- Merkel Cell Carcinoma: Patients surviving 9 years.
- Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years.
- Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors.
The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield."
The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type.
This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.
Are video's and live streaming now monetized on X?
What will the future of video analytics look like on X?
Let's take a closer look.
In this video:
@monetization_x@KSJ_Kreative@JacobCEdmunds